메뉴 건너뛰기




Volumn 80, Issue 6, 2008, Pages 937-941

Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations

Author keywords

AIDS; Enfuvirtide; Immune recovery; Multi drug resistance

Indexed keywords

EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; VIRUS RNA;

EID: 43249123806     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21138     Document Type: Article
Times cited : (7)

References (24)
  • 2
    • 33750338185 scopus 로고    scopus 로고
    • Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir
    • Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 80:10794-10801.
    • (2006) J Virol , vol.80 , pp. 10794-10801
    • Baxter, J.D.1    Schapiro, J.M.2    Boucher, C.A.3    Kohlbrenner, V.M.4    Hall, D.B.5    Scherer, J.R.6    Mayers, D.L.7
  • 4
    • 33645034361 scopus 로고    scopus 로고
    • First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases
    • Bourgarit A, Lascoux C, Palmer P, Tuleja E, Pintado C, Farge D, Sereni D. 2006. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases. AIDS 20:471-473.
    • (2006) AIDS , vol.20 , pp. 471-473
    • Bourgarit, A.1    Lascoux, C.2    Palmer, P.3    Tuleja, E.4    Pintado, C.5    Farge, D.6    Sereni, D.7
  • 5
    • 0032505017 scopus 로고    scopus 로고
    • Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection
    • Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J. 1998. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12:1591-1600.
    • (1998) AIDS , vol.12 , pp. 1591-1600
    • Carotenuto, P.1    Looij, D.2    Keldermans, L.3    de Wolf, F.4    Goudsmit, J.5
  • 6
    • 0031575431 scopus 로고    scopus 로고
    • Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals
    • Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. 1997. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185:621-628.
    • (1997) J Exp Med , vol.185 , pp. 621-628
    • Connor, R.I.1    Sheridan, K.E.2    Ceradini, D.3    Choe, S.4    Landau, N.R.5
  • 8
    • 33144485618 scopus 로고    scopus 로고
    • CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients
    • Agence Nationale de Recherche sur le Sida PRIMO Study Group
    • Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, Sinet M, Galimand J, Delfraissy JF, Venet A, Rouzioux C, Morlat P, Agence Nationale de Recherche sur le Sida PRIMO Study Group. 2006. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 42:709-715.
    • (2006) Clin Infect Dis , vol.42 , pp. 709-715
    • Goujard, C.1    Bonarek, M.2    Meyer, L.3    Bonnet, F.4    Chaix, M.L.5    Deveau, C.6    Sinet, M.7    Galimand, J.8    Delfraissy, J.F.9    Venet, A.10    Rouzioux, C.11    Morlat, P.12
  • 10
    • 1642423935 scopus 로고    scopus 로고
    • HIV biological variability unveiled: Frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use
    • Karlsson I, Antonsson L, Shi Y, Karlsson A, Albert J, Leitner T, Olde B, Owman C, Fenyo EM. 2003. HIV biological variability unveiled: Frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 17:2561-2569.
    • (2003) AIDS , vol.17 , pp. 2561-2569
    • Karlsson, I.1    Antonsson, L.2    Shi, Y.3    Karlsson, A.4    Albert, J.5    Leitner, T.6    Olde, B.7    Owman, C.8    Fenyo, E.M.9
  • 11
    • 0038576281 scopus 로고    scopus 로고
    • Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Jr., Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, TORO 1 Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175-2185.
    • Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Jr., Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, TORO 1 Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175-2185.
  • 14
    • 33746160257 scopus 로고    scopus 로고
    • HIV-1 coreceptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response
    • Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. 2006. HIV-1 coreceptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 194:238-246.
    • (2006) J Infect Dis , vol.194 , pp. 238-246
    • Melby, T.1    Despirito, M.2    Demasi, R.3    Heilek-Snyder, G.4    Greenberg, M.L.5    Graham, N.6
  • 15
    • 33846455806 scopus 로고    scopus 로고
    • Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: Fitness tampering or a case of persistent braking on entering?
    • Morse C, Maldarelli F. 2007. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: Fitness tampering or a case of persistent braking on entering? J Infect Dis 195:318-321.
    • (2007) J Infect Dis , vol.195 , pp. 318-321
    • Morse, C.1    Maldarelli, F.2
  • 17
    • 27944473910 scopus 로고    scopus 로고
    • Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Jr., Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. 2005. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 40:404-412.
    • Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Jr., Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. 2005. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 40:404-412.
  • 18
    • 33644834760 scopus 로고    scopus 로고
    • Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials
    • Raffi F, Katlama C, Saag M, Wilkinson M, Chung J, Smiley L, Salgo M. 2006. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 42:870-877.
    • (2006) Clin Infect Dis , vol.42 , pp. 870-877
    • Raffi, F.1    Katlama, C.2    Saag, M.3    Wilkinson, M.4    Chung, J.5    Smiley, L.6    Salgo, M.7
  • 19
    • 16244380203 scopus 로고    scopus 로고
    • Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization
    • Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. 2005. Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79:4991-4999.
    • (2005) J Virol , vol.79 , pp. 4991-4999
    • Reeves, J.D.1    Lee, F.H.2    Miamidian, J.L.3    Jabara, C.B.4    Juntilla, M.M.5    Doms, R.W.6
  • 20
    • 20844452242 scopus 로고    scopus 로고
    • Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, Sereni D, Viard JP, Delfraissy JF, Meyer L, SEROCO Cohort Study Group. 2005. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 192:46-55.
    • Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, Sereni D, Viard JP, Delfraissy JF, Meyer L, SEROCO Cohort Study Group. 2005. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 192:46-55.
  • 22
    • 0027440551 scopus 로고
    • Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype
    • Scarlatti G, Hodara V, Rossi P, Muggiasca L, Bucceri A, Albert J, Fenyo EM. 1993. Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology 197:624-629.
    • (1993) Virology , vol.197 , pp. 624-629
    • Scarlatti, G.1    Hodara, V.2    Rossi, P.3    Muggiasca, L.4    Bucceri, A.5    Albert, J.6    Fenyo, E.M.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.